Phasecraft and NVIDIA Benchmark 3,000 VQE Molecular Emulations Under Wellcome Leap Q4Bio Program

Phasecraft has constructed what the company claims is the largest dataset of variational quantum eigensolver (VQE) results to date, comprising more than 3,000 emulations across 13 distinct molecular systems. The benchmark work achieved a reported 15-fold speedup in modelling many-body systems compared to prior results, executed entirely on NVIDIA Hopper GPU processors hosted at the University of Nottingham using NVIDIA's cuQuantum toolkit. The emulations spanned quantum circuits of 4 to 32 qubits, with the bulk of computational focus concentrated in the 24–28 qubit range, a domain where classical computers retain the capacity to simulate quantum behavior.

Critically, the entire effort operated on classical computing infrastructure without access to quantum hardware. Phasecraft constructed a computational representation of what a quantum computer would calculate using non-quantum machines—currently the only viable method to generate training datasets at this volume and fidelity. While this approach operates within the classical simulation frontier, the company has framed the strategy as purposeful rather than expedient: building comprehensive training data now for quantum-enhanced density functional theory applications that will leverage quantum hardware once such systems achieve practical maturity.

This work is situated within the Wellcome Leap Quantum for Bio (Q4Bio) Challenge Program, a $50 million supported initiative designed to identify, develop, and demonstrate quantum computing applications relevant to healthcare and biological systems under real hardware and biological constraints. The program represents a structured effort to accelerate quantum technology adoption in human health, with Phasecraft participating in an advanced phase of the challenge.

Ashley Montanaro, Phasecraft's chief executive, articulated the strategic rationale: realizing quantum computing's fundamental promise requires relentlessly pushing the capabilities of today's most advanced classical hardware. The 15-fold speedup claim, while not accompanied by a peer-reviewed publication or detailed benchmark specification at announcement, reflects the company's effort to establish baseline performance metrics ahead of quantum processor availability. This positions Phasecraft and collaborators within a cohort of organizations advancing quantum computing's near-term utility in biological and pharmaceutical applications, a critical domain where quantum advantage has long been promised but practical systems remain nascent.